68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases
ConditionInflammatory Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Brest
About this trial
This single-center pilot study is designed to explore the preliminary utility of the \[68Ga\] Ga-FAPI imaging agent in positron emission tomography (PET) combined with computed tomography (CT) for a range of chronic inflammatory and fibrosing diseases. The study focuses on the potential of \[68Ga\] Ga-FAPI, a novel radiotracer targeting Fibroblast Activation Protein (FAP), to improve diagnostic accuracy in various medical conditions. Thirteen distinct clinical situations have been selected for this investigation, including rheumatoid arthritis, liver fibrosis, and systemic lupus, among others. This approach aims to ascertain the value of further clinical development in each area and refine the use of this imaging modality in routine care for both initial evaluation and ongoing monitoring of these diseases.
Eligibility criteria
Qualifiers
Patient aged 18 or over.
Affected by one of the pathologies concerned by the study (see Table 4)
Satisfying the consensus classification criteria for the pathology (Table 3).
Satisfying the corresponding clinical situation (Table 3).
Disqualifiers
Patients unable to consent.
Incapacitated adults.
Pregnant or breastfeeding women.
Patients refusing to participate in research.
Trial design
Treatments tested in this trial
- 68Ga-FAPI46
Treatment groups
390 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov